Health ❯ Healthcare

Adverse Events

Drug Safety Vaccine Safety Treatment-Related Adverse Events Medication Safety Safety Profile Clinical Trials Gastrointestinal Issues Clinical Outcomes Clinical Safety Treatment-Emergent Adverse Events Monitoring Systems Safety Profiles Treatment Safety Safety of Vaping Complications Clinical Trial Results Treatment Side Effects Treatment-Related Issues Vaccine Adverse Event Reporting System Injection-Site Reactions Clinical Study Findings Clinical Side Effects Drug Side Effects Vaccine Adverse Event Reporting System (VAERS) Infections Motor Neuropathy Medication Side Effects Immune-related Events Radiopharmaceutical Toxicities Liver Toxicity

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

Spyre Drug Meets Midstage Target in Ulcerative Colitis, Stock Rallies

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care